Perrigo CEO, Joseph Papa discusses his company's 11% Q2 profit rise, and its outlook on growth, with Mad Money's Jim Cramer.
A breakdown of the drug-maker's Q4 profit after reporting a loss a year earlier, with Andrew Witty, GlaxoSmithKline CEO.
Insight on the value that will be created by a transaction with Illumina, with Severin Schwan, Roche CEO, who discusses Roche's offer for Illumina.
During his presidential campaign in 2007, Republican candidate Mitt Romney promised that a trust overseeing his financial portfolio would shed any investments that conflicted with GOP positions toward Iran, China, stem cell research and other issues.
A breakdown of the pharmaceutical giant's earnings, with John Eade, Argus Research.
Weighing in on the pharmaceuticals company's fourth quarter earnings, with John Lechleiter, Eli Lilly chairman/president/CEO, who discusses patent expiration and the impact on business.
It’s rare for the world's leading pharmaceutical companies and other partners to work together to tackle an urgent global health issue. It’s time for this to change and our new coordinated effort – unlike previous siloed, disease-by-disease approaches – is the first step.
Cramer thinks big pharma stocks could soon pop, so here's his preferred plays.
Find out why he’s bullish on this biotech name.
Mad Money's Cramer, explains why Sanofi-Aventis is his favorite medical breakthrough stock, saying it has excellent management; its growth platforms are working; and it supplies a juicy dividend.
Paula Deen has been teaching comfort food cooks since 2002. On January 17, 2012, she announced her diagnosis of Type 2 diabetes. She also announced that she had become the spokesperson for the anti-diabetes drug Victoza. However, she’s hardly the only celebrity chef to make a questionable endorsement deal.
Amgen and Celgene, looking to boost oncology offerings, announced separate deals for small biotech companies Thursday, the latest in what analysts expect to be a major wave of biotech mergers.
And here’s how the “Mad Money” host suggests playing it.
If investors are looking for a big pharma play that hasn't already run up, then go bottom feeding with Johnson & Johnson, says Mad Money's Jim Cramer. It's not the best company in the business, but there are many positives in its future.
Keith Moore, MKM Partners, discusses how to play Roche's hostile bid for gene sequencer, Illumin, saying ILMN is likely to fight the takeover. Also an update on SanDisk's earnings, with the Fast Money crew.
Why the “Mad Money” host is bullish on both pharmaceutical stocks.
Mad Money's Jim Cramer, explains how big drug makers like, Pfizer and Bristol-Myers could pay off big time for investors.
The company reported quarterly earnings that beat analysts' expectations but issued guidance that disappointed traders, sending its shares briefly lower in pre-market trading on Tuesday.
Cramer thinks so. Here’s one stock, in particular, that he thinks could continue to rally.
Mad Money's Cramer says the worst of the patent expirations is over for many of the big pharma companies and that's why investors can now own the best of them, like Merck.